African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy

36Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Susceptibility to peripheral neuropathy during antiretroviral therapy with nucleoside reverse-transcriptase inhibitors was previously associated with a European mitochondrial DNA (mtDNA) haplogroup among non-Hispanic white persons. To determine whether nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy was related to mtDNA variation in non-Hispanic black persons, we sequenced mtDNA of participants from AIDS Clinical Trials Group study 384. Of 156 non-Hispanic black persons with genomic data, 51 (33%) developed peripheral neuropathy. In a multivariate model, African mtDNA subhaplogroup L1c was an independent predictor of peripheral neuropathy (odds ratio, 3.7 [95% confidence interval, 1.1-12.0]). An African mtDNA subhaplogroup is for the first time implicated in susceptibility to nucleoside reverse-transcriptase inhibitor-associated toxicity. © 2010 by the Infectious Diseases Society of America. All rights reserved.

Cite

CITATION STYLE

APA

Canter, J. A., Robbins, G. K., Selph, D., Clifford, D. B., Kallianpur, A. R., Shafer, R., … Hulgan, T. (2010). African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. Journal of Infectious Diseases, 201(11), 1703–1707. https://doi.org/10.1086/652419

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free